Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Financial support is being provided as a grant from the Government of India
The agreement will help ensure wider reach and access to patients in India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
